Citadel Advisors’s Biolase, Inc. BIOL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-39,829
| Closed | -$7.56K | – | 15762 |
|
|
2024
Q1 | $7.56K | Buy |
39,829
+26,011
| +188% | +$12.7K | ﹤0.01% | 13609 |
|
|
2023
Q4 | $15.5K | Buy |
+13,818
| New | +$19.7K | ﹤0.01% | 12838 |
|
|
2022
Q4 | – | Sell |
-175
| Closed | -$43K | – | 15620 |
|
|
2022
Q3 | $43K | Sell |
175
-83
| -32% | -$33.2K | ﹤0.01% | 11736 |
|
|
2022
Q2 | $118K | Buy |
+258
| New | +$142K | ﹤0.01% | 11242 |
|
|
2021
Q4 | – | Sell |
-35
| Closed | -$56K | – | 15016 |
|
|
2021
Q3 | $56K | Buy |
35
+27
| +338% | +$44.1K | ﹤0.01% | 13312 |
|
|
2021
Q2 | $14K | Sell |
8
-147
| -95% | -$273K | ﹤0.01% | 13553 |
|
|
2021
Q1 | $327K | Buy |
+155
| New | +$381K | ﹤0.01% | 10645 |
|
|
2020
Q4 | – | Sell |
-72
| Closed | -$49K | – | 11669 |
|
|
2020
Q3 | $49K | Buy |
72
+67
| +1,340% | +$62.8K | ﹤0.01% | 9610 |
|
|
2020
Q2 | $6K | Buy |
+5
| New | +$5.69K | ﹤0.01% | 9668 |
|
|
2019
Q1 | – | Sell |
-5
| Closed | -$13K | – | 10014 |
|
|
2018
Q4 | $13K | Buy |
+5
| New | +$16.1K | ﹤0.01% | 8876 |
|
|
2018
Q3 | – | Sell |
-4
| Closed | -$13K | – | 9818 |
|
|
2018
Q2 | $13K | Sell |
4
-3
| -43% | -$11.3K | ﹤0.01% | 8709 |
|
|
2018
Q1 | $36K | Buy |
+7
| New | +$39.3K | ﹤0.01% | 8009 |
|
|
2017
Q4 | – | Sell |
-4
| Closed | -$32K | – | 8541 |
|
|
2017
Q3 | $32K | Buy |
+4
| New | +$34.5K | ﹤0.01% | 7271 |
|
|
2017
Q1 | – | Sell |
-2
| Closed | -$36K | – | 8170 |
|
|
2016
Q4 | $36K | Hold |
2
| – | – | ﹤0.01% | 6942 |
|
|
2016
Q3 | $39K | Sell |
2
-3
| -60% | -$53.4K | ﹤0.01% | 6905 |
|
|
2016
Q2 | $69K | Buy |
5
+3
| +150% | +$47.5K | ﹤0.01% | 6328 |
|
|
2016
Q1 | $33K | Buy |
+2
| New | +$25.1K | ﹤0.01% | 6357 |
|
|
2015
Q3 | – | Sell |
-1
| Closed | -$22K | – | 9309 |
|
|
2015
Q2 | $22K | Sell |
1
-1
| -50% | -$24.4K | ﹤0.01% | 8113 |
|
|
2015
Q1 | $41K | Buy |
2
+1
| +100% | +$28.3K | ﹤0.01% | 7516 |
|
|
2014
Q4 | $44K | Buy |
+1
| New | +$31.3K | ﹤0.01% | 7287 |
|
Other funds holding BIOL
Citadel Advisors's BIOL Position: Q2 2024 in Review
Citadel Advisors sold out of Biolase, Inc. (BIOL) in Q2 2024, closing a stake of 39,829 shares — an estimated $7.56K sold.
Citadel Advisors first reported a position in BIOL in Q4 2014 and held it in 20 quarters. The position peaked at $327K in Q1 2021. 2 funds tracked by Wall St. Rank hold BIOL as of Q2 2024.
- Citadel Advisors reported no remaining Biolase, Inc. position as of Q2 2024 after selling out during the quarter.
- Citadel Advisors sold 39,829 Biolase, Inc. shares in Q2 2024, an estimated $7.56K.
- Citadel Advisors first reported a position in Biolase, Inc. in Q4 2014 and held it in 20 quarters.
- Citadel Advisors's Biolase, Inc. position peaked at $327K in Q1 2021.
- 2 funds tracked by Wall St. Rank held Biolase, Inc. as of Q2 2024.
Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.